Although this trial did not reveal a statistically significant difference in BAL samples between patients with malignant and benign lung diseases, there was evidence of a higher number of PD-1 + T lymphocytes in "proliferating" diseases, such as lung carcinoma or interstitial diseases. This evidence concerns the gene PDCD1 and lung carcinoma.